Skip to main content

Advertisement

Erratum To: The PTPN221858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden

The original article was published in Arthritis Research & Therapy 2007 9:R56

After publication of our recent article [1], we noticed an error in Table 6 'Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies'.

Under the heading of 'Anti-CCP antibody-positive', the first line should read 'HLA-shared epitope-negative', and the second line should read 'HLA-shared epitope-positive'. Similarly, under the heading 'Anti-CCP antibody-negative', the first line should read 'HLA-shared epitope-negative' and the second line should read 'HLA-shared epitope-positive'.

The correct table is given here as Table 1 (a corrected version of Table 6 [1]).

Table 1 Relative risk for developing rheumatoid arthritis in patients, stratified for anti-cyclic citrullinated peptide (anti-CCP) antibodies

References

  1. 1.

    Kokkonen H, Johansson M, Innala L, Jidell E, Rantapää-Dahlqvist S: The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther. 2007, 9: R56-10.1186/ar2214.

Download references

Author information

Correspondence to Solbritt Rantapää-Dahlqvist.

Additional information

The online version of the original article can be found at 10.1186/ar2214

Rights and permissions

Reprints and Permissions

About this article